Your browser doesn't support javascript.
loading
An analysis of benign prostatic hyperplasia surgical treatment reimbursement trends across Canada Examining provincial changes over the recent decade with comparison to cost of living changes.
Chakraborty, Anindyo; Elterman, Dean; Corsi, Nicholas; Bouhadana, David; Bailly, Gregory; Patel, Premal; McLellan, Rowen; Hickey, Liam; Costa, Daniel; Andrews, Matthew; Evans, Howard; Forbes, Connor M; Elmansy, Hazem; Meskawi, Malek; Bhojani, Naeem; Chughtai, Bilal; Zorn, Kevin C.
Afiliación
  • Chakraborty A; Faculty of Medicine and Health Sciences, McGill University, Montreal, QC; Canada.
  • Elterman D; Division of Urology, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Corsi N; Wayne State University School of Medicine, Detroit, MI, United States.
  • Bouhadana D; Division of Urology, McGill University, Montreal, QC, Canada.
  • Bailly G; Department of Urology, Dalhousie University, Halifax, NS, Canada.
  • Patel P; Section of Urology, University of Manitoba, Winnipeg, MB, Canada.
  • McLellan R; Department of Urology, Dalhousie University, Halifax, NS, Canada.
  • Hickey L; Department of Urology, Dalhousie University, Halifax, NS, Canada.
  • Costa D; Division of Urology, Queen Elizabeth Hospital, Charlottetown, PEI, Canada.
  • Andrews M; Division of Urology, Memorial University, St. John's, NL, Canada.
  • Evans H; Division of Urology, University of Alberta, Edmonton, AB, Canada.
  • Forbes CM; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Elmansy H; Department of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
  • Meskawi M; Department of Urology, Université de Montréal, Montreal, QC, Canada.
  • Bhojani N; Department of Urology, Université de Montréal, Montreal, QC, Canada.
  • Chughtai B; Department of Urology, Weill Cornell Medicine, New York, NY, United States.
  • Zorn KC; Department of Urology, Université de Montréal, Montreal, QC, Canada.
Can Urol Assoc J ; 18(8): 268-273, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38587981
ABSTRACT

INTRODUCTION:

A variety of procedures for the endoscopic surgical treatment of symptomatic benign prostatic hyperplasia (BPH) refractory to medical therapy have existed for decades. The present study examined trends in surgeon compensation for these treatments within Canada.

METHODS:

The physician fee schedule for BPH surgery across 10 Canadian provinces for the years 2010 and 2023 were obtained. A descriptive study examined first the provincial reimbursement for transurethral resection of prostate (TURP) and laser ablative/enucleation surgery; second, the difference in TURP reimbursement between 2010 and 2023; and third, the annual change in TURP reimbursement juxtaposed with the annual change in the provincial Consumer Price Index (CPI) and annual salary for the working population aged 35-44.

RESULTS:

Seven of 10 Canadian provinces reimburse laser BPH surgery equally to TURP. The average provincial TURP reimbursement is $545, ranging from $451 in Ontario to $688 in Saskatchewan. Since 2010, TURP reimbursement has varied by province from a 0% net change in Ontario to an increase of 21% in Nova Scotia. Reimbursement for TURP has increased at a slower pace than the local CPI, and for half of the provinces at a slower pace than the annual salary for people aged 35-44.

CONCLUSIONS:

The compensation model for endoscopic BPH surgery does not have a unified structure in Canada that is consistent across provinces, nor does it keep up with inflation, possibly impacting future recruitment, increasing geographic disparities, and most importantly, limiting the adoption of new BPH therapies.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Can Urol Assoc J Año: 2024 Tipo del documento: Article Pais de publicación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Can Urol Assoc J Año: 2024 Tipo del documento: Article Pais de publicación: Canadá